2020 Volume 2 Issue 1 Pages 24-29
Osteoporosis is associated with low bone density and pathological fractures induced by an imbalance in bone remodeling. It the most common bone disease and a social problem of an aging society. Norzoanthamine (NZ), a newly discovered marine alkaloid, has a suppressive effect on bone loss in osteoporosis animal models and is considered a candidate for anti-osteoporosis drug development. Truncated-norzoanthamine (TZ) is artificially synthesized, and possesses a structure similar to that of NZ. TZ and NZ have been shown to possess collagen protective activity. Here, we hypothesized that TZ also inhibits the bone loss observed in osteoporosis. We explored the effects of TZ treatment in an ovariectomized (OVX) osteoporosis mouse model. We observed that TZ suppressed the decrease in bone volume fraction, trabecular number, and bone mineral density in the femur of OVX mice as analyzed using micro-computed tomography, indicating an improvement in the bone mechanical characters. These findings indicate that TZ suppresses bone loss in OVX mice and suggest that TZ may offer therapeutic effects as a new anti-osteoporosis drug.